1
|
Chiche L, Marichez A, Rayar M, Simon A, Mohkam K, Muscari F, Boudjema K, Mabrut JY, Adam JP, Laurent C. Liver transplantation: Do not abandon T-tube drainage-a multicentric retrospective study of the ARCHET research group. Updates Surg 2024:10.1007/s13304-024-02008-w. [PMID: 39541088 DOI: 10.1007/s13304-024-02008-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2023] [Accepted: 09/25/2024] [Indexed: 11/16/2024]
Abstract
Biliary complications remain a real issue in liver transplantation (LT). Despite meta-analyses, the anastomosis technique, especially the use of biliary drain as T-Tube drain (TT) or transcystic drain, remains controversial. This study conducted by the ARCHET research group examine the incidence and types of biliary complications (BC) after LT according to the presence or absence of a biliary drain. 1485 patients with LT surgery between 2009 to 2015 in 4 LT centers were included, divided into 3 groups: no drain (ND n = 442), transcystic drain (TCD, n = 169) and TT(n = 874).The T-Tube group includes 3 techniques: transanastomotic, subanastomotic and tunneled retroperitoneal. Fistula and biliary stricture (AS) rates were studied. The risk factors of BC were investigated by multivariate analysis. The BC rate was lower in the TT group (17% TT, 25% TCD, 31% ND, p < 0.05), the complication rate Dindo-Clavien grade ≥ III is higher in the ND group (24% vs. 10% TT p < 0.05). Arterial complication has been found as a risk factor of BC with the multivariate analysis (p < 0.01, OR 1.86 [1.20-2.84]). In addition, the TT decreased by 5 the risk of AS (p < 0.05, OR 0.19 [0.12-0.28]). The fistula rate does not differ regardless of the reconstruction mode. In this study, biliary drain decreases the rate of BC. The findings confirmed the role of T-tube insertion in prevention of AS regardless of the way it is set up.
Collapse
Affiliation(s)
- Laurence Chiche
- Department of Hepato-Bilio-Pancreatic Surgery and Liver Transplantation, Haut Lévêque Hospital, CHU de Bordeaux, Bordeaux, France.
- Inserm, UMR 1312 - Team 3 "Liver Cancers and Tumoral Invasion", Bordeaux Institute of Oncology, University of Bordeaux, Bordeaux, France.
| | - Arthur Marichez
- Department of Hepato-Bilio-Pancreatic Surgery and Liver Transplantation, Haut Lévêque Hospital, CHU de Bordeaux, Bordeaux, France
- Inserm, UMR 1312 - Team 3 "Liver Cancers and Tumoral Invasion", Bordeaux Institute of Oncology, University of Bordeaux, Bordeaux, France
| | - Michel Rayar
- Department of Hepatobiliary and Digestive Surgery, CHU Rennes, Rennes, France
- Department of Research INSERM CIC 1414, University Rennes, Rennes, France
| | - Agathe Simon
- Department of Hepato-Bilio-Pancreatic Surgery and Liver Transplantation, Haut Lévêque Hospital, CHU de Bordeaux, Bordeaux, France
| | - Kayvan Mohkam
- Department of General Surgery & Liver Transplantation, Hospices Civils de Lyon, Croix-Rousse CHU Lyon, Lyon, France
- Department of Research, INSERM Unit U1052, Cancer Research Center of Lyon, Lyon, France
| | - Fabrice Muscari
- Department of Digestive Surgery, Toulouse University Hospital, 31059, Toulouse, France
- Department of Research, INSERM, CRCT, University Toulouse, Toulouse, France
| | - Karim Boudjema
- Department of Digestive Surgery, Toulouse University Hospital, 31059, Toulouse, France
- Department of Research, INSERM, CRCT, University Toulouse, Toulouse, France
| | - Jean-Yves Mabrut
- Department of General Surgery & Liver Transplantation, Hospices Civils de Lyon, Croix-Rousse CHU Lyon, Lyon, France
- Department of Research, INSERM Unit U1052, Cancer Research Center of Lyon, Lyon, France
| | - Jean-Philippe Adam
- Department of Hepato-Bilio-Pancreatic Surgery and Liver Transplantation, Haut Lévêque Hospital, CHU de Bordeaux, Bordeaux, France
| | - Christophe Laurent
- Department of Hepato-Bilio-Pancreatic Surgery and Liver Transplantation, Haut Lévêque Hospital, CHU de Bordeaux, Bordeaux, France
- Inserm UMR 1312, Team 8 "Biotherapy Genetics and Oncology", Bordeaux Institute of Oncology, University of Bordeaux, Bordeaux, France
| |
Collapse
|
2
|
Truong R, Moore HB, Sauaia A, Kam I, Pshak T, Adams M, Conzen K, Zimmerman MA, Wachs M, Bak T, Pomposelli J, Pomfret E, Nydam TL. Choledochoduodenostomy continues to be a safe alternative for biliary reconstruction in deceased-donor liver transplantation. Am J Surg 2022; 224:1398-1402. [PMID: 36400602 DOI: 10.1016/j.amjsurg.2022.10.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2022] [Revised: 09/25/2022] [Accepted: 10/13/2022] [Indexed: 12/14/2022]
Abstract
Debate continues as to whether choledochoduodenostomy (CDD) can be used instead of Roux-en-Y choledochojejunostomy (CDJ) when duct-to-duct (DTD) is not an option. We hypothesized that CDD and CDJ had similar rates of complications. All deceased-donor liver transplantations from September 2011 to March 2020 were categorized by biliary reconstruction. Primary outcomes were bleeding, bile leak, anastomotic stricture, and cholangitis. Of the 1,086 patients, 812 (74.8%) received a DTD; 225 (20.7%) received a CDD; and 49 (4.5%) received a CDJ. Cholangitis was significantly higher in CDJ compared to DTD and CDD (26.5% vs 6% vs 13.8%, p < 0.0001). When controlling for significant confounders, CDJ had 10.2 higher odds of cholangitis (95% CI 4.4-23.2) compared to DTD, and 3.3 higher odds compared to CDD (95% CI 1.4-7.8). When compared to DTD, CDJ and CDD had significantly lower odds of stricture. CDD continues to be a safe alternative for biliary reconstruction in deceased-donor liver transplantation.
Collapse
Affiliation(s)
- Ronald Truong
- University of Colorado School of Medicine, Division of Transplant Surgery, Department of Surgery, 1635 Aurora Court, 7th Floor, Aurora, CO, 80045, USA
| | - Hunter B Moore
- University of Colorado School of Medicine, Division of Transplant Surgery, Department of Surgery, 1635 Aurora Court, 7th Floor, Aurora, CO, 80045, USA
| | - Angela Sauaia
- University of Colorado School of Medicine, Division of Transplant Surgery, Department of Surgery, 1635 Aurora Court, 7th Floor, Aurora, CO, 80045, USA; University of Colorado Denver School of Public Health, Department of Health Systems, Management and Policy, 13011 E. 17th Place, Room E-3309, Aurora, CO, 80045, USA
| | - Igal Kam
- University of Colorado School of Medicine, Division of Transplant Surgery, Department of Surgery, 1635 Aurora Court, 7th Floor, Aurora, CO, 80045, USA
| | - Thomas Pshak
- University of Colorado School of Medicine, Division of Transplant Surgery, Department of Surgery, 1635 Aurora Court, 7th Floor, Aurora, CO, 80045, USA
| | - Megan Adams
- University of Colorado School of Medicine, Division of Transplant Surgery, Department of Surgery, 1635 Aurora Court, 7th Floor, Aurora, CO, 80045, USA
| | - Kendra Conzen
- University of Colorado School of Medicine, Division of Transplant Surgery, Department of Surgery, 1635 Aurora Court, 7th Floor, Aurora, CO, 80045, USA
| | - Michael A Zimmerman
- Medical College of Wisconsin, Division of Transplant Surgery, 9200 W. Wisconsin Avenue, Milwaukee, WI, 53226, USA
| | - Michael Wachs
- University of Colorado School of Medicine, Division of Transplant Surgery, Department of Surgery, 1635 Aurora Court, 7th Floor, Aurora, CO, 80045, USA
| | - Thomas Bak
- University of Colorado School of Medicine, Division of Transplant Surgery, Department of Surgery, 1635 Aurora Court, 7th Floor, Aurora, CO, 80045, USA
| | - James Pomposelli
- University of Colorado School of Medicine, Division of Transplant Surgery, Department of Surgery, 1635 Aurora Court, 7th Floor, Aurora, CO, 80045, USA
| | - Elizabeth Pomfret
- University of Colorado School of Medicine, Division of Transplant Surgery, Department of Surgery, 1635 Aurora Court, 7th Floor, Aurora, CO, 80045, USA
| | - Trevor L Nydam
- University of Colorado School of Medicine, Division of Transplant Surgery, Department of Surgery, 1635 Aurora Court, 7th Floor, Aurora, CO, 80045, USA.
| |
Collapse
|
4
|
Bhutiani N, Jones JM, Wei D, Goldstein LJ, Martin RCG, Jones CM, Cannon RM. A cost analysis of early biliary strictures following orthotopic liver transplantation in the United States. Clin Transplant 2018; 32:e13396. [PMID: 30160322 DOI: 10.1111/ctr.13396] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Revised: 08/20/2018] [Accepted: 08/25/2018] [Indexed: 12/17/2022]
Abstract
INTRODUCTION To date, the financial burden of biliary strictures (BS) after orthotopic liver transplantation (OLT) has remained largely unassessed. This study sought to approximate perioperative costs associated with early BS and delineate where in the hospital these costs are incurred. METHODS The Premier Healthcare Database was queried for patients undergoing OLT between 2010 and 2016. Patients who did and did not develop early BS were compared with respect to perioperative costs and outcome variables. Multivariable regression models were used to estimate differences between groups. RESULTS Patients who developed early BS had a longer length of stay (LOS) (35.3 days vs 17.8 days, P < 0.001) and were less likely to be discharged home (odds ratio = 0.45, P = 0.003). Development of early BS was associated with an incremental cost increase of $81 881 (45.8%, P < 0.001). The greatest relative cost increases were in radiology (+163.5%) and respiratory therapy (+157.1%), while the greatest absolute increase was in room and board (+$27 589). CONCLUSIONS Early BS after OLT result in higher costs stemming from longer LOS and increased need for various diagnostic studies and therapies. In addition to incentivizing measures that may prevent early BS, hospitals should account for these factors when developing payment schemes for OLT with payors.
Collapse
Affiliation(s)
- Neal Bhutiani
- Division of Transplantation, Hiram C. Polk Jr, MD Department of Surgery, University of Louisville, Louisville, Kentucky
| | - Jordan M Jones
- Division of Transplantation, Hiram C. Polk Jr, MD Department of Surgery, University of Louisville, Louisville, Kentucky
| | - David Wei
- Epidemiology, Medical Devices, Johnson & Johnson, New Brunswick, New Jersey
| | - Laura J Goldstein
- Franchise Health Economics and Market Access, Ethicon, Somerville, New Jersey
| | - Robert C G Martin
- Division of Transplantation, Hiram C. Polk Jr, MD Department of Surgery, University of Louisville, Louisville, Kentucky
| | - Christopher M Jones
- Division of Transplantation, Hiram C. Polk Jr, MD Department of Surgery, University of Louisville, Louisville, Kentucky
| | - Robert M Cannon
- Division of Transplantation, Hiram C. Polk Jr, MD Department of Surgery, University of Louisville, Louisville, Kentucky
| |
Collapse
|